Your browser is no longer supported. Please, upgrade your browser.
GLPG [NASD]
Galapagos NV
Index- P/E- EPS (ttm)-1.69 Insider Own- Shs Outstand65.41M Perf Week-1.19%
Market Cap5.52B Forward P/E- EPS next Y-4.72 Insider Trans- Shs Float43.14M Perf Month-19.12%
Income- PEG- EPS next Q-1.33 Inst Own11.77% Short Float2.24% Perf Quarter-32.96%
Sales- P/S- EPS this Y15.60% Inst Trans- Short Ratio2.82 Perf Half Y-35.58%
Book/sh25.49 P/B3.31 EPS next Y1.90% ROA- Target Price95.54 Perf Year-61.30%
Cash/sh- P/C- EPS next 5Y0.71% ROE- 52W Range81.37 - 233.14 Perf YTD-14.77%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.43% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low1.92% ATR2.97
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)31.03 Volatility1.84% 2.63%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.73 Prev Close84.36
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume342.37K Price82.93
Recom2.80 SMA20-9.42% SMA50-15.59% SMA200-42.69% Volume94,595 Change-1.70%
Feb-23-21Upgrade BofA Securities Underperform → Neutral $93 → $94
Feb-19-21Upgrade Raymond James Mkt Perform → Outperform
Feb-11-21Downgrade Citigroup Buy → Neutral
Jan-19-21Upgrade Morgan Stanley Equal-Weight → Overweight $159 → $129
Nov-19-20Initiated Maxim Group Buy $170
Oct-21-20Downgrade Goldman Neutral → Sell
Aug-25-20Downgrade Jefferies Buy → Hold
Aug-24-20Downgrade H.C. Wainwright Buy → Neutral $270 → $123
Aug-19-20Upgrade Citigroup Neutral → Buy
Aug-19-20Downgrade Barclays Overweight → Equal Weight
Jul-10-20Downgrade Stifel Buy → Hold $298 → $193
Mar-30-20Upgrade Jefferies Hold → Buy $232
Mar-18-20Upgrade RBC Capital Mkts Underperform → Sector Perform $175 → $157
Feb-25-20Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-24-20Downgrade BofA/Merrill Neutral → Underperform
Feb-20-20Downgrade RBC Capital Mkts Sector Perform → Underperform $175
Jan-06-20Downgrade JP Morgan Overweight → Neutral
Dec-18-19Downgrade Citigroup Buy → Neutral
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $174 → $169
Mar-03-21 03:20AM  
Feb-23-21 06:55AM  
Feb-22-21 02:20PM  
07:21AM  
Feb-20-21 06:15PM  
Feb-19-21 06:30PM  
12:15PM  
01:05AM  
Feb-18-21 04:01PM  
Feb-15-21 10:00PM  
Feb-13-21 03:00PM  
Feb-11-21 03:28PM  
02:10PM  
11:18AM  
08:25AM  
Feb-10-21 02:52PM  
11:10AM  
09:00AM  
Feb-09-21 04:01PM  
Jan-21-21 02:08AM  
Jan-12-21 11:54AM  
Jan-11-21 04:01PM  
Jan-06-21 09:30AM  
Jan-05-21 12:15PM  
Jan-04-21 04:05PM  
04:01PM  
Dec-29-20 11:50PM  
Dec-28-20 07:00AM  
Dec-26-20 03:24PM  
Dec-23-20 09:20PM  
12:00PM  
Dec-18-20 11:00AM  
Dec-17-20 09:35AM  
Dec-16-20 09:59PM  
04:33PM  
01:42PM  
01:37PM  
07:15AM  
Dec-15-20 04:15PM  
04:15PM  
Dec-12-20 06:50PM  
07:20AM  
Dec-11-20 12:44PM  
Dec-10-20 05:17PM  
06:56AM  
Dec-04-20 04:01PM  
Dec-01-20 04:01PM  
08:08AM  
Nov-30-20 04:01PM  
Nov-28-20 06:45AM  
Nov-23-20 04:15PM  
Nov-09-20 04:01PM  
Nov-05-20 04:15PM  
04:01PM  
Nov-02-20 04:01PM  
Oct-28-20 06:06PM  
Oct-27-20 11:21AM  
Oct-23-20 02:05PM  
Oct-22-20 04:22PM  
Oct-16-20 07:15AM  
Oct-15-20 04:19PM  
Oct-13-20 03:10PM  
Oct-12-20 09:15AM  
09:15AM  
Oct-01-20 01:54PM  
Sep-29-20 04:01PM  
Sep-28-20 03:01PM  
09:44AM  
Sep-27-20 05:52AM  
Sep-25-20 01:00PM  
01:00PM  
07:48AM  
02:14AM  
02:14AM  
Sep-18-20 04:01PM  
Sep-14-20 10:28AM  
09:28AM  
05:45AM  
Sep-13-20 06:17PM  
Sep-11-20 08:05AM  
Sep-10-20 10:30PM  
Sep-01-20 11:15PM  
Aug-28-20 07:45AM  
06:10AM  
Aug-26-20 01:30AM  
Aug-25-20 10:45PM  
Aug-21-20 01:54AM  
Aug-20-20 05:28PM  
11:45AM  
Aug-19-20 08:01PM  
12:18PM  
12:00PM  
10:42AM  
03:46AM  
02:48AM  
12:29AM  
Aug-18-20 07:25PM  
Aug-12-20 04:01PM  
Aug-06-20 04:01PM  
Jul-24-20 08:14AM  
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.A r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.